Shenzhen OK Biotech Technology Co., Ltd. (SZOB)
Product Categories

     Shenzhen OK Biotech Technology Co., Ltd.(SZOB)

     HK Add: 6/F, Fo Tan Industrial Centre, 26-28 Au Pui Wan St ,Fo Tan, Shatin, Hongkong

     China mainland Add: 8F, Fuxuan Building, No. 46, East Heping Rd, Longhua New  District,  Shenzhen, PRC China

     Email: nicole@ok-biotech.com

        smile@ok-biotech.com

     Web: www.ok-biotech.com

     Tel: +852 6679 4580

Pregabalin (148553-50-8)

Pregabalin, marketed under the brand name Lyrica among others, is a medication used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Its use for epilepsy is as an add-on therapy for partial seizures with or without secondary generalization in adults.

 

What is Pregabalin anesthetic raw powder?

Pregabalin, marketed under the brand name Lyrica among others, is a medication used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Its use for epilepsy is as an add-on therapy for partial seizures with or without secondary generalization in adults. Some off-label uses of pregabalin include restless leg syndrome, prevention of migraines, social anxiety disorder, and alcohol withdrawal. When used before surgery it does not appear to affect pain after surgery but may decrease the use of opioids.

 


 

The usages of Pregabalin anesthetic raw powder

 

Seizures

Pregabalin is useful when added to other treatments, when those other treatments are not controlling partial epilepsy. Its use alone is less effective than some other seizure medications. It is unclear how it compares to gabapentin for this use.

 

Neuropathic pain

The European Federation of Neurological Societies recommends pregabalin as a first line agent for the treatment of pain associated with diabetic neuropathy, post-herpetic neuralgia, and central neuropathic pain. A minority obtain substantial benefit, and a larger number obtain moderate benefit. Other first line agents, including gabapentin and tricyclic antidepressants, are given equal weight as first line agents, and unlike pregabalin, are available as less expensive generics.

 

Pregabalin is not recommended for certain other types of neuropathic pain such as trigeminal neuralgia and its use in cancer-associated neuropathic pain is controversial. There is no evidence for its use in the prevention of migraines and gabapentin has been found not to be useful. It has been examined for the prevention of post-surgical chronic pain, but its utility for this purpose is controversial.

 

Pregabalin is generally not regarded as efficacious in the treatment of acute pain. Trials examining the utility of pregabalin for the treatment of acute post-surgical pain, no effect on overall pain levels was observed, but people did require less morphine and had fewer opioid-related side effects. Several possible mechanisms for pain improvement have been discussed.

 


 

 

Anxiety disorders

The World Federation of Biological Psychiatry recommends pregabalin as one of several first line agents for the treatment of generalized anxiety disorder, but recommends other agents such as SSRIs as first line treatment for obsessive-compulsive disorder and post-traumatic stress disorder. It appears to have anxiolytic effects similar to benzodiazepines with less risk of dependence.

The effects of pregabalin appear after 1 week of use and is similar in effectiveness to lorazepam, alprazolam, and venlafaxine, but pregabalin has demonstrated superiority by producing more consistent therapeutic effects for psychosomatic anxiety symptoms. Long-term trials have shown continued effectiveness without the development of tolerance, and, in addition, unlike benzodiazepines, it has a beneficial effect on sleep and sleep architecture, characterized by the enhancement of slow-wave sleep. It produces less severe cognitive and psychomotor impairment compared to those drugs; it also has a low potential for abuse and dependence and may be preferred over the benzodiazepines for these reasons.

 


 

The Side effects of Pregabalin anesthetic raw powder

Pregabalin has been shown to produce therapeutic effects that are similar to other controlled substances. In a study with recreational users of sedative and hypnotic drugs, a 450 mg dose of pregabalin resulted in subjective ratings of a "good drug effect" and "high" and "liking" similar to 30 mg of diazepam. In clinical studies, pregabalin showed a side effect profile similar to other central nervous system depressants.

 

 


 

 

Adverse drug reactions associated with the use of pregabalin anesthetic raw powder include:

 

Very common (>10% of patients): dizziness, drowsiness.


Common (1–10% of patients): blurred vision, diplopia, increased appetite and subsequent weight gain, euphoria, confusion, vivid dreams, changes in libido (increase or decrease), irritability, ataxia, attention changes, feeling high, abnormal coordination, memory impairment, tremors, dysarthria, parasthesia, vertigo, dry mouth and constipation, vomiting and flatulence, erectile dysfunction, fatigue, peripheral edema, feeling the effects of drunkenness, abnormal walking, asthenia, nasopharyngitis, increased creatine kinase level.


Infrequent (0.1–1% of patients): depression, lethargy, agitation, anorgasmia, hallucinations, myoclonus, hypoaesthesia, hyperaesthesia, tachycardia, excessive salivation, hypoglycaemia, sweating, flushing, rash, muscle cramp, myalgia, arthralgia, urinary incontinence, dysuria, thrombocytopenia, kidney calculus
Rare (<0.1% of patients): neutropenia, first degree heart block, hypotension, hypertension, pancreatitis, dysphagia, oliguria, rhabdomyolysis, suicidal thoughts or behavior.

 


 

The dose of Pregabalin anesthetic raw powder

 

Usual Adult Dose for Diabetic Neuropathy:

-Initial dose: 50 mg orally 3 times a day
-Titration: The dose may be increased to 100 mg orally 3 times a day within 1 week based on efficacy and tolerability


-Maximum dose: 100 mg orally 3 times a day in patients with a creatinine clearance of at least 60 mL/min

 

Comment:

-This drug may be taken with or without food.

Use: Management of neuropathic pain associated with diabetic peripheral neuropathy

Usual Adult Dose for Postherpetic Neuralgia:

 

-Initial dose: 75 mg orally 2 times a day OR 50 mg orally 3 times a day 
-Titration: The dose may be increased to 100 mg orally 3 times a day within 1 week based on efficacy and tolerability


-Maintenance dose: 75 to 150 mg orally 2 times a day OR 50 to 100 mg orally 3 times a day (150 to 300 mg/day) in patients with a creatinine clearance of at least 60 mL/min
-Maximum dose: Patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 300 mg/day and who are able to tolerate this drug, may be treated with up to 300 mg orally 2 times a day or 200 mg orally 3 times a day (due to the dose-dependent adverse effects and the higher rate of treatment discontinuation due to adverse events, dosing above 300 mg/day should be reserved only for those patients who have ongoing pain and are tolerating 300 mg daily)

 


 

 

Comment:
-This drug may be taken with or without food.

Use: Management of postherpetic neuralgia

Usual Adult Dose for Epilepsy:

-Initial dose: 75 mg orally 2 times a day OR 50 mg orally 3 times a day
-Maintenance dose: 150 mg/day to 600 mg/day (the total daily dose should be divided and given either 2 or 3 times a day)


-Maximum dose: 600 mg/day in 2 or 3 divided doses based on individual patient response and tolerability

 

Comments:
-This drug may be taken with or without food.
-The efficacy of add-on therapy in patients taking gabapentin has not been evaluated in controlled trials; therefore, dosing recommendations for the use of this combination cannot be offered.

 

Use: Adjunctive therapy for adult patients with partial onset seizures

Usual Adult Dose for Fibromyalgia:

 

-Initial dose: 75 mg orally 2 times a day (150 mg/day)
-Titration: The dose may be increased to 150 mg orally 2 times a day (300 mg/day) within 1 week based on efficacy and tolerability


-Maintenance dose: 300 to 450 mg/day in 2 divided doses
-Maximum dose: Patients who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg orally 2 times a day (450 mg/day)

 

Comments:
-This drug may be taken with or without food.

Use: Management of fibromyalgia

Although pregabalin was also studied at 600 mg/day, there is no evidence that this dose confers additional benefit and this dose was less well tolerated. In view of the dose-dependent adverse reactions, treatment with doses above 450 mg/day is not recommended.

 

Usual Adult Dose for Neuropathic Pain:

-Initial dose: 75 mg orally 2 times a day
-Titration: The dose may be increased to 150 mg orally 2 times a day within 1 week based on efficacy and tolerability


-Maintenance dose: 150 to 600 mg/day in divided doses


-Maximum dose: Patients who do not experience sufficient pain relief after 2 to 3 weeks of treatment with 150 mg orally 2 times a day and who tolerate this drug may be treated with up to 300 mg orally 2 times a day

 

Comments:
-This drug may be taken with or without food.

 

Use: Neuropathic pain associated with spinal cord injury

 

 

 


 

 

Hot Tags: 148553-50-8,Pregabalin,Pregabalin raw,buy Pregabalin raw,manufacturer powder, supplier, factory, buy raw materials of Pregabalin, Pregabalin usages, Pregabalin dosage,Pregabalin side effect,Pregabalin is a medication used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder,anesthetic raw powder,anesthetic raw,anesthetic powder,
I want to leave a message
Contact Us
Address: HK: 6/F,Fo Tan Industrial Centre,26-28 Au Pui Wan St,Fo Tan,Shatin,Hongkong Shenzhen: 8F, Fuxuan Building, No. 46, East Heping Rd, Longhua New District, Shenzhen, PRC China
Tel: +852 6679 4580
 Fax:+852 6679 4580
 E-mail:smile@ok-biotech.com
Shenzhen OK Biotech Technology Co., Ltd.(SZOB)
Share:
Verification: c5916f6aec73893e